Key Findings

The Phase 2 VENTURE study evaluated weekly subcutaneous VK2735, a dual GIP/GLP-1 receptor agonist developed by Viking Therapeutics, in adults with obesity. According to the PubMed-indexed publication, the trial demonstrated:

  • Dose-dependent weight loss across multiple dose cohorts
  • Up to 14.7% mean weight loss from baseline at the 13-week primary endpoint
  • A safety profile consistent with the incretin receptor agonist class, with gastrointestinal adverse events (nausea, vomiting, diarrhoea) being the most commonly reported

The 13-week treatment period is relatively short compared to the 68-week duration of pivotal trials for approved agents such as semaglutide (STEP programme) and tirzepatide (SURMOUNT programme), but the magnitude of weight loss observed is notable.

Context: The Multi-Receptor Agonist Landscape

VK2735 enters a competitive field of next-generation incretin therapies. Key comparators include:

  • Tirzepatide (dual GIP/GLP-1): Approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). SURMOUNT trials showed up to 22.5% weight loss at 72 weeks.
  • Retatrutide (triple GIP/GLP-1/glucagon): Phase 3 TRIUMPH programme ongoing.
  • Survodutide (dual GLP-1/glucagon): Phase 3 ASCEND programme ongoing.
  • CagriSema (amylin + GLP-1): REDEFINE programme showed 22.7% weight loss in Phase 3.

VK2735's mechanism (dual GIP/GLP-1) is the same as tirzepatide's. The key question for late-stage development is whether VK2735 offers differentiated efficacy, tolerability, or dosing convenience.

Implications for Peptide Researchers

The VENTURE results reinforce several trends relevant to researchers tracking the peptide therapeutic landscape:

  1. Multi-receptor agonism continues to outperform monoagonism: The weight loss magnitudes seen with dual and triple agonists in short-duration trials continue to exceed what was achievable with first-generation GLP-1 monoagonists.
  2. Short-duration signals are strong: The 14.7% weight loss in just 13 weeks, if sustained, would project to competitive long-term results.
  3. Class-level safety profile: Gastrointestinal effects remain the dominant adverse event, consistent across the incretin class.

UK Relevance

VK2735 has no UK marketing authorisation. It is not available on the NHS or via private prescription. As an investigational compound, it falls under the MHRA's framework for clinical trial medicines. UK-based researchers should note that any research-grade material purporting to be VK2735 would require careful vendor verification, as the compound is not in commercial production.

What's Next

Viking Therapeutics is advancing VK2735 into later-stage clinical development. Researchers should monitor ClinicalTrials.gov for the initiation of Phase 3 trials and watch for longer-duration efficacy and safety data. The company is also developing an oral formulation of VK2735, which would represent a significant differentiator if successful.

For more information on related compounds, see our profiles on tirzepatide, retatrutide, survodutide, and VK2735.

References

  1. PubMed. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. PMID: 41508550. Available at: https://pubmed.ncbi.nlm.nih.gov/41508550/
  2. ClinicalTrials.gov. VK2735 trial listings. Available at: https://clinicaltrials.gov/search?term=VK2735
  3. Viking Therapeutics corporate communications. Available at: https://www.vikingtherapeutics.com

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.